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High fidelity CRISPR/Cas9 increases 
precise monoallelic and biallelic 
editing events in primordial germ 
cells
Alewo Idoko-Akoh, Lorna Taylor, Helen M. Sang & Michael J. McGrew  
Primordial germ cells (PGCs), the embryonic precursors of the sperm and egg, are used for the 
introduction of genetic modifications into avian genome. Introduction of small defined sequences 
using genome editing has not been demonstrated in bird species. Here, we compared oligonucleotide-
mediated HDR using wild type SpCas9 (SpCas9-WT) and high fidelity SpCas9-HF1 in PGCs and show 
that many loci in chicken PGCs can be precise edited using donors containing CRISPR/Cas9-blocking 
mutations positioned in the protospacer adjacent motif (PAM). However, targeting was more 
efficient using SpCas9-HF1 when mutations were introduced only into the gRNA target sequence. 
We subsequently employed an eGFP-to-BFP conversion assay, to directly compare HDR mediated by 
SpCas9-WT and SpCas9-HF1 and discovered that SpCas9-HF1 increases HDR while reducing INDEL 
formation. Furthermore, SpCas9-HF1 increases the frequency of single allele editing in comparison 
to SpCas9-WT. We used SpCas9-HF1 to demonstrate the introduction of monoallelic and biallelic 
point mutations into the FGF20 gene and generate clonal populations of edited PGCs with defined 
homozygous and heterozygous genotypes. Our results demonstrate the use of oligonucleotide donors 
and high fidelity CRISPR/Cas9 variants to perform precise genome editing with high efficiency in PGCs.
The chicken is a useful animal model for biological research and can be used to produce biopharmaceutical prod-
ucts that cannot be produced in mammalian bioreactor systems1,2. Chicken meat and eggs derived from 70 billion 
chickens yearly are an important source of high quality protein, vitamins and minerals in the global economy3. 
The ability to precisely edit the chicken genome to introduce or test genetic variants will aid the study of gene 
function, define combinatorial allelic contribution to disease resistance/resilience and production phenotypes 
and will lead to the uncovering of beneficial alleles which could be introduced into breeding programmes for the 
improvement of poultry welfare and sustainable production.
The application of precision genome editing to bird species has failed to keep pace with that of other mam-
malian species. In mammals, germline genetic engineering may be achieved through pronuclear injection of 
the zygote4, injection of genetically modified embryonic stem cells into the blastocyst5, and somatic cell nuclear 
transfer of genetically modified somatic cells (SCNT)6,7. These methods are not regularly practised in bird spe-
cies because the single-cell zygote is difficult to access and manipulate and cultured avian embryonic stem cells 
do not contribute to the formation of the germ lineage8,9. In contrast to other species, heritable genetic changes 
may be introduced into chicken through the genetic manipulation of primordial germ cells (PGCs), the stem cell 
precursors of the sperm and egg, which can be propagated in culture and will contribute to the germline when 
reintroduced into surrogate host chick embryos10–12.
Targeted genetic modification in chicken PGCs was first demonstrated through classical gene targeting by 
homologous recombination (HR) to generate immunoglobulin-knockout chickens13. The observation that DNA 
Double-stranded breaks (DSBs) stimulate and increase the frequency of HR led to the development of artifi-
cial site-specific nucleases including ZFNs, TALENs and CRISPR/Cas9 with the goal of improving the efficiency 
of site-specific gene targeting14,15. Artificial site-specific nucleases are guided to a specific genomic site by pro-
grammable DNA-binding modules where they create a DSB. The cleaved DNA is immediately repaired by either 
The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Easter Bush Campus, 
Midlothian, EH25 9RG, UK. Correspondence and requests for materials should be addressed to M.J.M. (email: mike.
mcgrew@roslin.ed.ac.uk)
Received: 28 June 2018
Accepted: 17 September 2018
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCIEnTIfIC RepoRts |  (2018) 8:15126  | DOI:10.1038/s41598-018-33244-x
non-homologous end-joining (NHEJ) or the HR pathway16–18. NHEJ is the predominant pathway that repairs 
DSBs that occur in all phases of the cell cycle and often leads to the generation of insertion/deletion (INDEL) 
mutations19. The HR or homology-directed repair (HDR) pathway is active in the S and G2 phase of the cell 
cycle and is used to repair a double-stranded DNA break when there is an available DNA donor containing a 
region that is homologous to the region surrounding the severed DNA ends16,20,21. The high fidelity of HDR is 
constrained by the nucleotide composition of the repair template and this constraint is exploited in genome engi-
neering to introduce a desired nucleotide change. TALENs and CRISPR/Cas9-mediated NHEJ have been used 
to produce several knockout-chickens through the generation of INDELs in chicken PGCs22,23. Homologous 
recombination mediated by TALENs and CRISPR/Cas9 have also been performed in chicken PGCs to introduce 
targeted transgenes24,25. However, the use of site-specific nucleases to perform precision editing of a single to few 
nucleotides has not been demonstrated in avian species.
Genome editing mediated by CRISPR/Cas9 and short single stranded oligodeoxynucleotides (ssODN) donors 
has been used to perform small precise genetic changes in many cell types and organisms26–37 and in a chicken 
somatic cell line38. However, use of ssODN donors for gene correction can be toxic to cells by causing a G2/M cell 
cycle arrest39, and activating cellular immune responses40. HDR targeting therefore requires careful optimization 
for each cell type. Following CRISPR/Cas9-induced DSBs, DNA repair with ssODN donors occurs through the 
synthesis-dependent strand annealing (SDSA) pathway of HDR41. However, the accuracy of HDR editing may 
be distorted by the incorporation of INDELs at the target site in a second round of repair due to re-cleaving by 
CRISPR/Cas942,43. Previous studies have shown that the introduction of Cas9-blocking mutations in the PAM are 
effective in preventing re-editing of genetic loci while blocking mutations positioned in the gRNA target sequence 
have variable efficacy35.
High fidelity CRISPR/Cas9 nucleases with improved specificity have been developed to reduce the frequency 
of off-target events associated with wild type Streptococcus pyogenes Cas9 (SpCas9-WT)44–46. These high fidelity 
Cas9 variants harbour amino acid substitutions that significantly reduce activation of cleavage at target sites 
that are not perfectly complementary to the gRNA sequence. Here, we investigated a high fidelity Cas9 variant, 
SpCas9-HF145, for introducing defined nucleotide changes in chicken PGCs using ssODN donors. First, we opti-
mised the use of ssODN donors as repair templates for CRISPR/Cas9-mediated HDR in cultured chicken PGCs. 
We then directly compared HDR editing between SpCas9-WT and SpCas9-HF1 using ssODN donors containing 
CRISPR/Cas9-blocking mutations positioned in the PAM and show that many loci in chicken PGCs can be effi-
ciently edited using SpCas9-HF1. Using ssODN donors containing mutations in the guide sequence only, we also 
showed that SpCas9-HF1 is more efficient than SpCas9-WT in introducing precise genome edits in the absence 
of CRISPR/Cas9-blocking mutation in the PAM. We subsequently used a eGFP-to-BFP conversion assay47 to 
directly compare HDR mediated by SpCas9-WT and SpCas9-HF1 and found that SpCas9-HF1 increases the 
efficiency of accurate HDR editing while reducing INDEL formation at the target site. Finally, we combined 
SpCas9-HF1 and ssODN donors to demonstrate precise biallelic and monoallelic introduction of the chicken 
scaleless genetic variant associated with the heat tolerance featherless phenotype by introducing two defined 
nucleotide substitutions into the FGF20 gene48–50. Our results demonstrate the use of high fidelity CRISPR/Cas9 
variants to perform precise HDR genome editing with high efficiency in chicken PGCs.
Results
High fidelity Cas9 variant, SpCas9-HF1, shows efficient HDR editing in chicken PGCs. We first 
tested SpCas9-WT and high fidelity SpCas9-HF1 to edit multiple loci in chicken PGCs. SpCas9-HF1 contains 
4 amino acid substitutions that prevent activation of the nuclease at mismatched targets45. To directly com-
pare SpCas9-HF1 and SpCas9-WT, we transferred the codon-changing mutations from the VP12 vector which 
encodes SpCas9-HF1 into PX459 vector which encodes a mammalian-codon optimised SpCas9-WT as well as 
puromycin resistance33 (Fig. 1). We named this modified vector HF-PX459.
To compare HDR editing between SpCas9-WT and SpCas9-HF1 in chicken PGCs, we designed gRNAs to 
target exon 3 of FGF20 (FGF20-gRNA1) and exon 2 of CXCR4 (CXCR4-gRNA), and used previously described 
gRNAs to target exon 3 of ovalbumin (OVA) and exon 1 of ovomucoid (OVM) (OVA-gRNA for ovalbumin and 
OVM-gRNA for ovomucoid)23 (Fig. 2). In order to directly analyse HDR efficiency without sequencing PCR prod-
ucts, we used antisense repair templates that introduce an EcoRI recognition site for RFLP analysis51,52. CXCR4 
is expressed in chicken PGCs while FGF20, ovalbumin and ovomucoid are transcriptionally inactive. To target 
each locus, we used ssODN donors containing mutations of the gRNA seed sequence and PAM to insert an EcoRI 
recognition sequence (122-nt CXCR4-ssODN for CXCR4, 126-nt FGF20-ssODN for FGF20, 127-nt OVA-ssODN 
for ovalbumin and 128-nt OVM-ssODN for ovomucoid; Fig. 2). We co-transfected the corresponding ssODN 
donor and gRNA with SpCas9-HF1 or SpCas9-WT into PGCs and then treated with puromycin to select for 
Cas9-transfected cells. We performed two independent targeting experiments for each locus. To analyse HDR, 
we PCR amplified the target site and performed EcoRI RFLP digest assay on the PCR products to estimate HDR 
efficiency. In CXCR4, we observed an average HDR efficiency of 50.5% in PGCs targeted with SpCas9-HF1 
and 35.5% with SpCas9-WT (Fig. 2A and Supplementary Fig. S2). For ovomucoid, the average HDR efficiency 
was 42.5% using SpCas9-HF1 and 39.5% with SpCas9-WT (Fig. 2B and Supplementary Fig. S2), whereas the 
average HDR efficiency was 63.5% with SpCas9-HF1 and 62.5% with SpCas9-WT for ovalbumin (Fig. 2C 
and Supplementary Fig. S2). For FGF20, we also tested the NHEJ inhibitors, SCR7 and L755507, reported to 
increase HDR efficiency34,53. We observed an average HDR efficiency of 48.5% and 3.5% with SpCas9-HF1 and 
SpCas9-WT respectively without using NHEJ inhibitors while no HDR improvement was observed with either 
SCR7 or L755507 treatment (Fig. 2D and Supplementary Fig. S2). Thus, NHEJ inhibitors do not increase targeting 
efficiency in PGCs and targeting efficiencies were equal or slightly better using SpCas9-HF1 in combination with 
donor containing PAM mutations.
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We next tested whether introducing single-nucleotide blocking mutations into the PAM-distal region of the 
gRNA target sequence was sufficient to achieve high HDR without introducing a blocking mutation in the PAM. 
Cleavage activity of Cas9 was shown to be severely reduced when mismatches are present in the seed region 
(first 8–12 nucleotides proximal of the PAM) of the gRNA target sequence54–57. However, mismatches were tol-
erated in the PAM-distal non-seed region of the gRNA target and are associated with off-target mutagenesis by 
SpCas9-WT58–60. To test the efficiency of accurate HDR when introducing single nucleotide mutations into the 
non-seed region of the gRNA target sequence, we designed ssODN donors containing one to three substitu-
tions of the last 14–20 PAM-distal nucleotides (120-nt CXCR4-ssODN2 for CXCR4, 128-nt OVM-ssODN2 for 
ovomucoid, 127-nt OVA-ssODN2 for ovalbumin, 127-nt OVA-ssODN3 for ovalbumin and 126-nt FGF20-ssODN2 
for FGF20; Fig. 2, right panels). The substitutions introduce a restriction site for RFLP analysis. We transfected 
and analysed cells as above. For CXCR4, we observed an average HDR efficiency of 17.5% using SpCas9-HF1 
and 0.0% with SpCas9-WT when CXCR4-ssODN2 was supplied as repair template (Fig. 2A and Supplementary 
Fig. S2). For ovomucoid, the average HDR efficiency was 34.0% using SpCas9-HF1 and 0.5% with SpCas9-WT 
when OVM-ssODN2 was supplied as repair template (Fig. 2B and Supplementary Fig. S2). For ovalbumin, the 
average HDR efficiency was 58.5% using SpCas9-HF1 and 53.5% using SpCas9-WT when OVA-ssODN2 was 
supplied as repair template (Fig. 2C and Supplementary Fig. S2). When OVA-ssODN3 was used as a repair tem-
plate containing a single base pair change in the PAM distal guide region, we observed an average HDR efficiency 
of 43.5% using SpCas9-HF1 and 1.0% using SpCas9-WT (Fig. 2C and Supplementary Fig. S2). For FGF20, we 
observed an average HDR efficiency of 37.5% with SpCas9-HF1 and 3.5% with SpCas9-WT when FGF20-ssODN2 
was supplied as repair template (Fig. 2D and Supplementary Fig. S2). We also compared symmetrical and asym-
metrical ssODNs as well as a double stranded repair template carried in plasmid but observed similar levels of 
HDR at FGF20 (data not shown). Our results show that SpCas9-HF1, in comparison to SpCas9-WT, is effective 
for achieving precise introduction of single nucleotide changes into the non-seed region of the gRNA target 
sequence. These results demonstrate the accuracy and versatility of SpCas9-HF1.
SpCas9-HF1 reduces INDEL formation at target site in comparison to SpCas9-WT. To better 
quantitate HDR and INDEL formation mediated by SpCas9-WT and SpCas9-HF1, we used an assay that con-
verts enhanced green fluorescent protein (eGFP) to blue fluorescent protein (BFP) after editing events47. The 
eGFP-to-BFP conversion assay simultaneously quantifies total HDR and NHEJ events in a targeted population. 
We targeted PGCs isolated from homozygous transgenic chicken ubiquitously and constitutively expressing 
eGFP (GFP-PGCs; Fig. 3A) with a validated gRNA (GFP-gRNA) which was co-delivered with SpCas9-WT or 
SpCas9-HF1 and a ssODN donor carrying three nucleotide substitutions (BFP-ssODN; Fig. 3A) designed to con-
vert eGFP to BFP47. In this case the 20 nucleotide GFP-gRNA begins with a C nucleotide which reduces tran-
scription from the U6 promoter61. BFP-ssODN donor contains a C-to-G substitution that converts Threonine 
(T) to Serine (S), a T-to-C substitution that converts Tyrosine (Y) to Histidine (H) and a synonymous T-to-G 
substitution. The C-to-G substitution (the 1st nucleotide of the gRNA seed sequence) and the T-to-C substitution 
(1st nucleotide of the PAM) serve as Cas9-blocking mutations to prevent re-editing and increase HDR accuracy 
of SpCas9-WT. eGFP is converted to BFP by a Y66H amino acid substitution. Error-free editing of the eGFP 
sequence will lead to the expression of BFP while the presence of INDELs, even after recombinational repair, will 
result in no BFP or eGFP expression due to a shift in the reading frame. Before transfection, 99.9% of gated living 
cells expressed eGFP. Transfection with SpCas9-WT vector resulted in 30.3% of PGCs expressing BFP and the 
remaining 69.7% did not express GFP indicating INDEL formation. In contrast, transfection with SpCas9-HF1 
vector resulted in 68.2% of PGCs expressing BFP and the remaining 31.7% did not express eGFP (Fig. 3B). The 
HDR and INDEL levels obtained with SpCas9-WT in this assay are consistent with reports by other researchers 
Figure 1. Schematic representation of CRISPR/Cas9 vectors used in this study. HF-PX459 and PX459 vectors 
differ by only four amino acids in the encoded Cas9 protein. HF-PX459 vector encodes SpCas9-HF1 while 
PX459 encodes SpCas9-WT. The U6 promoter drives sgRNA expression while expression of Cas9 protein and 
puromycin resistance (PuroR) is driven by the CAG promoter.
www.nature.com/scientificreports/
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using human cell lines47,62. Two distinct populations of BFP-expressing PGCs were observed for both SpCas9-WT 
and SpCas9-HF1 (Fig. 3C, top panel) and determined their median fluorescent intensity (MFI). We determined 
that the population with the lower MFI of approximately 2000 units was monoallelic for BFP and contained 
Figure 2. Efficient oligonucleotide-template HDR editing across multiple loci using SpCas9-HF1. Left panels: 
PAM-region mutated templates. Right panels: Guide-region mutated templates. All HDR ssODN donors were 
complementary to the gRNA target strand and were symmetric around the cut site except for FGF20-ssODN. 
gRNA sequences are highlighted in blue. PAMs are highlighted in purple. Blue arrowheads indicate Cas9 
cleavage sites. Insertions, deletions and substitutions in HDR donors are highlighted in red. Black arrowheads 
indicate undigested PCR substrate. Red arrowheads indicate digested PCR products. (−) untreated substrate. 
(+) treated substrate. (See Figure S9 for uncropped images).
www.nature.com/scientificreports/
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Figure 3. SpCas9-HF1 increases HDR by reducing INDEL formation. (A) An eGFP expression cassette was 
integrated in the MAD1L1 gene. CAG promoter drives eGFP expression. The gRNA sequence is highlighted in 
blue while the PAM is highlighted in purple. Blue arrowhead indicates Cas9 cleavage site. Substitutions in the 
BFP-ssODN donor are highlighted in red. BFP-ssODN is a 122-nt HDR template that is complementary to the 
target strand. (B) Flow cytometric detection of BFP-expressing PGCs and non-fluorescent PGCs to quantify 
HDR and INDEL levels respectively. (C) Flow cytometric quantification of BFP-expression PGCs (top panels) 
and mean fluorescent intensity of BFP-expressing PGCs (bottom panels). (D) Alignment of sequences of cloned 
PCR products from PGCs in quadrants Q1 and Q4.
www.nature.com/scientificreports/
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INDELs on the second GFP allele while the population with an MFI of approximately 4000 units was biallelic for 
BFP by TIDE analysis63 of the PCR sequencing traces of these populations (Fig. 3C, bottom panel, Supplementary 
Fig. S3). Interestingly, we noticed that the proportion of BFP PGCs transfected with SpCas9-HF1 that was biallelic 
for BFP was 53.9% while 44.7% was monoallelic for BFP. For PGCs transfected with SpCas9-WT, 25.4% of BFP 
PGCs was biallelic for BFP while 73.6% was monoallelic for BFP. This indicates that SpCas9-HF1 increases the 
efficiency of biallelic HDR by up to two-fold by reducing INDEL formation. Also, the absence of PGCs express-
ing only eGFP or co-expressing eGFP and BFP is indicative of the high mutagenic activity of CRISPR/Cas9 and 
is similar to previous observation47,62. Our results show that using SpCas9-HF1 with ssODN donors containing 
Cas9-blocking mutations positioned in the gRNA sequence increases HDR levels by more than 2-fold with a 
concomitant decrease in INDEL formation in comparison to SpCas9-WT.
SpCas9-HF1 efficiently introduces heterozygous biallelic edits in comparison to 
SpCas9-WT. In the experiment above (Fig. 3), we observed that less than 0.2% of PGCs were heterozygous for 
eGFP and BFP using SpCas9-HF1 while no BFP-eGFP heterozygotes were obtained using SpCas9-WT. This obser-
vation reflects the experimental difficulty in generating specific heterozygous mutations since most CRISPR/Cas9 
editing events are biallelic and cells with monoallelic HDR edits usually contain INDELs on the second allele35,64. 
A strategy that has been employed for editing single alleles in human IPS cells uses a mixture of two ssODN donor 
templates containing Cas9-blocking mutations with an observed efficiency of 0.1%35. Since SpCas9-HF1 increases 
HDR levels as well as the efficiency of biallelic HDR by reducing INDEL formation (Fig. 3B and C), we reasoned 
that SpCas9-HF1 could increase the efficiency of editing individual alleles using two ssODN donors. We com-
pared SpCas9-WT and SpCas9-HF1 by performing eGFP-to-BFP editing of single eGFP alleles in GFP-PGCs to 
produce eGFP/BFP heterozygote cells. We designed a second repair template (GFP-ssODN) containing three syn-
onymous nucleotide substitutions to preserve the amino acid sequence of eGFP (Fig. 4A). GFP-PGCs were then 
transfected with SpCas9-WT or SpCas9-HF1 vectors and equimolar amounts of GFP-ssODN and BFP-ssODN 
donors and then analysed by flow cytometry for expression of BFP and eGFP. The results from two independent 
experiments are shown in Fig. 4B. 1.5% of PGCs targeted with SpCas9-WT co-expressed eGFP and BFP while 
9.2% of PGCs targeted with SpCas9-HF1 were eGFP/BFP co-expressing cells reflecting an almost 7-fold increase 
in HDR frequency in comparison to SpCas9-WT. Direct sequencing of PCR products from single-cell clones 
co-expressing eGFP and BFP confirmed incorporation of nucleotide changes in ssODN donors into the individ-
ual eGFP alleles (Fig. 4C). Similar to our previous result (Fig. 3B), we observed that 74.4% of PGCs targeted with 
SpCas9-WT did not express eGFP or BFP in comparison to 31.8% for PGCs targeted with SpCas9-HF1 (Fig. 4B). 
These results illustrate that SpCas9-HF1 increases the frequency of editing individual alleles by increasing HDR 
efficiency while reducing INDEL formation.
Precise biallelic introgression of a genetic variant into chicken PGCs. We next demonstrated the 
introgression of specific genetic variants into PGCs. The scaleless mutation (sc/sc) is a single A-to-T substitution 
in exon 3 of FGF20 (535A > T) which creates a premature stop codon resulting in a truncated FGF20 protein that 
leads to a complete loss of feather development48. We selected three gRNAs (Supplementary Fig. S1) targeting for 
the location of the scaleless variant but only gRNA1 (FGF20-gRNA1) containing a cut site that is 12 bp away from 
the target nucleotide was active with both SpCas9-WT and SpCas9-HF1 (Fig. 5A and Supplementary Fig. S1). 
We designed an ssODN donor (Sca-ssODN) containing a Cas9-blocking synonymous point mutation in the PAM 
(AGG → AGA) and the scaleless mutation (535A > T) which was 6 bp downstream of the 3′ end of the PAM 
(Fig. 5A). We anticipated that the 12 bp distance from the cut site to the edit site (cut-to-edit distance) would 
reduce editing accuracy. It has previously been shown that the efficiency of heterologous DNA incorporation 
is reduced as the distance between the site of edit and Cas9 cleavage site increases and the highest efficiency is 
achived within a distance of 8 to 10 bp27,35,65. To address the cut-to-edit distance, we used an asymmetric design 
for the ssODN donor containing a left homology arm (HA) of 36 bp and right HA of 91 bp to provide increased 
homology on the side containing the edited PAM and the 535A > T mutation. This asymmetric repair template 
design was previously described to increase HDR efficiency in human HEK293 and K562 cell lines by up to 60%66.
To introduce the 535A > T (sc/sc) gene variant, we transfected PGCs with FGF20-gRNA1 and SpCas9-HF1 or 
SpCas9-WT with Sca-ssODN and then sequenced PCR products directly from 38 single-cell clonal populations 
isolated from two independent experiments to analyse their mutational status and zygosity. The results are shown 
in Table 1 and Fig. 5B.
We found that 7.9% of isolated clones transfected with SpCas9-WT contained precise monoallelic intro-
duction of the PAM substitution and the scaleless mutation on one chromosome while the other chromosome 
contained INDELs. The other 92.1% of isolated clones contained INDELs on both chromosomes with no incor-
poration of the scaleless mutation. We note that this frequency is much higher than the INDEL frequency meas-
ured for this guide using the T7 endonuclease I assay (Fig. S1). We attribute this difference to inefficiencies of 
the T7 endonuclease I assay67. In contrast, 41.8% of single-cell clones transfected with SpCas9-HF1 were precise 
biallelic HDR clones. We discovered that 36.8% of the SpCas9-HF1 clones contained accurate biallelic incor-
poration of the PAM substitution and the 535A > T (sc/sc) mutation (Fig. 5B). We also noted that the PAM and 
535A > T mutation was incorporated into only one chromosome (sc/+) in two SpCas9-HF1 clones (5.3% of 
isolated clones), while the second chromosome only contained the PAM substitution. Furthermore, we observed 
that 18.4% of the total SpCas9-HF1 clones were precise monoallelic HDR clones containing the PAM substitution 
and 535A > T mutation on one chromosome while the other chromosome contained INDELs. The high rate of 
biallelic editing is similar to observations in human IPSCs and mouse ES cells targeted with SpCas9-WT35,64. We 
noted that the 535A > T mutation was incorporated into 37 out of 39 HDR alleles (94.9%) in SpCas9-HF1 clones.
We next attempted to introduce the 535A > T gene variant into a single allele (sc/+) by providing two repair 
templates. Our previous result (Fig. 4B) showed that SpCas9-HF1 increases the overall efficiency of editing 
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individual alleles using two ssODN donors whereas isolation of biallelically edited heterozygotes was barely 
detectable when SpCas9 was used. Consequently, we only tested SpCas9-HF1 in the following experiment. We 
designed two donors to introduce silent mutations on one allele while incorporating the 535A > T mutation 
Figure 4. SpCas9-HF1 increases the frequency of single allele editing (A) GFP-ssODN contains three 
synonymous substitutions to preserve that amino acid sequence of eGFP. Substitutions in ssODN donors are 
highlighted in red. gRNA target sequence is coloured blue, PAM is highlighted in purple, blue arrowhead 
indicates Cas9 cleavage site. (B) Flow cytometric detection and quantification of PGCs co-expressing GFP and 
BFP. (C) Sanger sequencing traces of direct PCR products from representative isolated single cell clones co-
expressing GFP and BFP. Red box encloses region containing edits.
www.nature.com/scientificreports/
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into the second allele using Sca-ssODN (Fig. 5A). The first silent donor (Silent-ssODN) contained 2 synony-
mous substitutions in the PAM (AGG → CGC) to preserve the FGF20 amino acid sequence. In the second silent 
donor (Silent2-ssODN), the PAM mutation was the same as in Sca-ssODN (AGG → AGA) while a synonymous 
Figure 5. Introgression of scaleless 535A > T mutation into FGF20. (A) Strategy for introduction of 535A > T 
mutation into Exon 3. The gRNA directs cleavage 12 bp from the position of the targeted nucleotide change. 
Substitutions in ssODN donors are highlighted in red. PAM is highlighted in purple. Blue arrowhead indicates 
Cas9 cleavage site. All ssODN donors are complementary to the target strand. (B–D) Frequency of the mutation 
genotypes of isolated single-cell clones based on ssODN donor used for allelic repair. Representative sequence 
traces show mutation genotypes of HDR clones. Black arrows indicate PAM mutations, red arrows indicate Sc 
mutations, blue arrow shows biallelic 535A > C mutation.
www.nature.com/scientificreports/
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substitution 535A > C was made in the same position as the 535A > T mutation 12 bp from the cleavage site to 
maintain the cut-to-edit distance between templates. Since Silent-ssODN showed more complementarity to the 
target region than Sca-ssODN due to the 535A > T substitution, we asked whether the two silent repair templates 
would be used at different frequencies for allelic repair when used with Sca-ssODN.
We transfected SpCas9-HF1 with FGF20-gRNA1 and an equimolar mixture of Sca-ssODN donor and 
Silent-ssODN (Sca-ssODN/Silent-ssODN mixture) or an equimolar mixture of Sca-ssODN and Silent2-ssODN 
(Sca-ssODN/Silent2-ssODN mixture) for comparison. We performed two independent experiments and iso-
lated a total of 18 single-cell clonal populations in each experiment. The results are shown in Tables 2 and 3 and 
Fig. 5C,D.
Biallelic HDR editing with the co-incorporation of PAM mutations into the two alleles was observed in 
69.5% of the clones targeted with the Sca-ssODN/Silent-ssODN mixture in contrast to 55.5% observed with the 
Sca-ssODN/Silent2-ssODN mixture (Fig. 5C). Remarkably, 25% of the clones contained the heterozygous edit for 
535A > T (sc/+) in which the two alleles were independently repaired by the two ssODN templates (Sca/Silent 
and Sca/Silent2; Tables 2 and 3). 13.9% of the isolated clones targeted with the Sca-ssODN/Silent-ssODN mixture 
were biallelically repaired by Sca-ssODN (Sca/Sca) whereas 25.0% of the clones were biallelically repaired by 
Silent-ssODN (Silent/Silent) (Table 2 and Fig. 5C). One clone (Sca/Sca*Wt) was biallelically repaired by Sca-ssODN 
and was homozygous for the PAM substitution but heterozygous for 535A > T (sc/+) indicating partial introduc-
tion of edits in one chromosome (Table 2). We noted that 30 out of the 53 HDR alleles (56.6%) were repaired by 
Silent-ssODN when Sca-ssODN and Silent-ssODN were used together. Similarly, Silent2-ssODN repaired 57.7% of 
the 52 HDR alleles generated when it was used with Sca-ssODN. Using Sca-ssODN and Silent2-ssODN together, we 
also observed that 22.2% of the total isolated clones were biallelically repaired by Silent2-ssODN (Silent2/Silent2) 
while 13.9% were biallelically repaired by Sca-ssODN (Sca/Sca and Sca/Sca*Wt). We identified 2 clones bialleli-
cally harbouring the AGG → AGA PAM substitution on the two alleles but containing 535A > C mutation on only 
one allele indicating partial introduction of edits. While the proportion of biallelically edited heterozygous clones 
were the same using the two ssODN donor mixtures (Sca-ssODN/Silent-ssODN and Sca-ssODN/Silent2-ssODN 
mixtures), we observed that clones with monoallelic HDR contained INDELs on the other allele. The 535A > T 
substitution was incorporated into 22 out of 23 HDR alleles (95.7%) repaired by Sca-ssODN in clones targeted 
with Sca-ssODN/Silent-ssODN mixture. Similarly, the 535A > T substitution was incorporated into all 22 HDR 
alleles (100.0%) repaired by Sca-ssODN in clones targeted with Sca-ssODN/Silent2-ssODN mixture.
Discussion
The validation of many genotypes requires the accurate creation of specific biallelic or monoallelic combinations 
by the introduction of single to several nucleotide changes. Building on previous work, our results illustrate an 
efficient strategy for introducing defined sequence changes into PGCs using the CRISPR/Cas9 system. We show 
that ssODNs serve as efficient donors for precision genome editing in chicken PGCs. To the best of our knowl-
edge, this has not been previously demonstrated for avian species or for germline stem cells. Following CRISPR/
Cas9-induced DSBs, DNA repair with ssODN donors occurs through the synthesis-dependent strand annealing 
(SDSA) pathway41. We observe that HDR efficiencies with ssODN donors in chicken PGCs are up to 5-fold higher 
than previously reported using double stranded templates24,25. Previous reports show that Cas9 activity may be 
Clone genotype Sca/Sca Sca/Sca*Wt Sca/INDEL INDEL/INDEL Total
SpCas9-WT clones 0 0 3 (7.9%) 35 (92.1%) 38 (100%)
SpCas9-HF1 clones 14 (36.8%) 2 (5.3%) 7 (18.4%) 15 (39.5%) 38 (100%)
HDR Biallelic Biallelic Monoallelic N/A N/A
Table 1. Edits of the FGF20 gene based on ssODN donor used for allelic repair in single-cell clones targeted 
with Sca-ssODN and SpCas9 or SpCas9-HF1 (Supplementary Figs S4 and S5).
Clone genotype Sca/Silent Sca/Sca Silent/Silent Sca/Sca*Wt Sca/INDEL Silent/INDEL INDEL/INDEL Total
SpCas9-HF1 clones 9 (25.0%) 5 (13.9%) 10 (27.8%) 1 (2.8%) 2 (5.6%) 1 (2.8%) 8 (22.2%) 36 (100%)
HDR Biallelic Biallelic Biallelic Biallelic Monoallelic Monoallelic N/A N/A
Table 2. Edits of the FGF20 gene based on ssODN donor used for allelic repair in single-cell clones targeted 
with SpCas9-HF1 and a mixture of Sca-ssODN and Silent-ssODN (Supplementary Fig. S6).
Clone genotype Sca/Silent2 Sca/Sca Silent2/Silent2 Silent2/Silent2*Wt Sca/INDEL Silent2/INDEL INDEL/INDEL Total
SpCas9-HF1 clones 9 (25.0%) 5 (13.9%) 8 (22.2%) 2 (5.6%) 3 (8.3%) 1 (2.8%) 8 (22.2%) 36 (100%)
HDR Biallelic Biallelic Biallelic Biallelic Monoallelic Monoallelic N/A N/A
Table 3. Edits of FGF20 gene based on ssODN donor used for allelic repair single-cell clones targeted with 
SpCas9-HF1 and a mixture of Sca-ssODN and Silent2-ssODN (Supplementary Fig. S7).
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repressed in transcriptionally inactive targets in heterochromatin and nucleosomal DNA68–70. We found that 
HDR efficiency was unaffected by the transcriptional state of the targeted gene in PGCs (Fig. 2).
Similar to a recent report in human cells71, we observed using the GFP-to-BFP conversion assay that 
SpCas9-HF1 increases HDR levels while reducing INDEL formation (Figs 3 and 4). Since enhanced specificity 
Cas9 variants discriminate against targets bearing mismatches in the non-seed region of the gRNA target and pre-
vent nuclease activation44–46, the higher HDR efficiency observed with SpCas9-HF1 in our results can be attrib-
uted to the high fidelity of the nuclease which proof-reads the gRNA target sequence before activating cleavage, 
thereby reducing re-editing of the repaired target site and leading to higher levels of HDR in the two alleles and 
lowering INDEL formation. As a consequence, base pair changes can be efficiently introduced into the non-seed 
sequence of the guide region using SpCas9-HF1 without introducing a blocking mutation into the neighbouring 
PAM site (Fig. 2). This enhancement in HDR accuracy by SpCas9-HF1 directly increases the efficiency of editing 
single alleles to generate PGCs with specific heterozygous genotypes (Figs 4 and 5C,D).
In human IPS cells, use of SpCas9-WT and ssODN donors containing appropriate CRISPR/Cas9-blocking 
mutations positioned in the PAM site increased HDR levels by up to a 100-fold while mutations positioned in the 
gRNA target sequence showed variable efficacy35. At this observed efficiency, one correctly edited homozygous 
clone was isolated for every 20 to 40 single-cell clones targeted using a single ssODN template, whereas hundreds 
of single cell clones were needed to isolate a biallelically edited heterozygous clone repaired using two ssODN 
templates35. In contrast to these results, using a single ssODN repair template containing CRISPR/Cas9-blocking 
PAM mutations and SpCas9-HF1 to introduce the scaleless mutation into the FGF20 locus, we found that 4 to 
5 correctly edited clones were isolated for every 10 clones screened. In contrast, we were unable to isolate a 
clone with precise biallelic HDR using SpCas9-WT from the number of clones that we screened which suggests 
that many more clones will need to be picked. In our attempt to introduce the scaleless mutation into one allele 
(sc/+), we were able to isolate 2 correctly edited clones containing heterozygous biallelic edits for every 10 clones 
screened. It must be noted that we performed single cell culturing in a growth-factors-optimised, serum-free and 
feeder-free culture medium11. In our protocol, chicken PGCs proliferate more rapidly (21-hr doubling time) than 
the PGCs cultured in high-serum chicken PGC medium10.
A major requirement for the use of SpCas9-HF1 is that the 20-nt gRNA sequence must be perfectly comple-
mentary to the genomic target to achieve high on-target editing efficiency45. When using the U6 promoter to 
drive sgRNA expression, the requirement for a 5′- G base in the sgRNA sequence limits the use of SpCas9-HF1 in 
targets that do not have a 5′G, and adding an extra G significantly reduces on on-target efficiency45,72. However, it 
has been shown that using alternative promoters such as the U3 promoter to express sgRNA, expressing sgRNAs 
from synthetic tRNA-sgRNA constructs or using hammerhead ribozyme-linked sgRNAs leads to similar levels of 
on-target efficiencies SpCas9-WT72,73.
In targeting the FGF20 gene with SpCas9-HF1, we found that the scaleless 535A > T nucleotide change located 
6 bp downstream of the PAM and 12 bp away from the cut site of the gRNA was incorporated biallelically at a rate 
of >90% in isolated HDR clones containing PAM mutations. In comparison to our results, a 12 bp cut-to-edit 
distance was shown to result in <20% biallelic incorporation of the edit in biallelic HDR clones in human IPS 
cells35. Surprisingly, we also observed that all INDEL clones targeted using SpCas9-WT and Sca-ssODN did not 
contain the 535A > T substitution or PAM mutation suggesting that these clones never underwent HDR editing 
event. The only CRISPR/Cas9-blocking mutation in the Sca-ssODN template is a single nucleotide substitution 
in the PAM (AGG → AGA) which may not be sufficient to block re-cutting of the repaired site by Cas9. It has 
been shown in human cells that NGA PAMs may have up to 40% activity in some loci74,75. Interestingly, we 
also observed that some clones contained the 535A > T substitution on only one allele while the PAM mutation 
was present on the two alleles suggestive of partial or incomplete HDR and has been reported by others27,31,35. 
This may be indicative of a cut-to-distance dependence mechanism in the incorporation of single nucleotide 
edits in chicken PGCs as previously reported in human cells and mouse zygotes27,35. Furthermore, we observed 
that Silent-ssODN was used more frequently for allelic repair when it was mixed with Sca-ssODN whereas 
Silent2-ssODN and Sca-ssODN were used at almost equal frequency. The absence of the distal mutation 12 bp 
away from the cut site in Silent-ssODN may have favoured this donor and has been previously observed in 
human cells35. Also, we did not see any evidence of template switching for allelic repair between Sca-ssODN and 
Silent-ssODN which has been reported to occur in human cells41. While we used an asymmetric ssODN donor to 
introduce scaleless 535A > T nucleotide change into FGF20 (Fig. 5A) based on the reported ability of this template 
design to increase HDR66, we are unable to tell from our results if asymmetric repair templates are more efficient 
than symmetric templates in enhancing HDR in chicken PGCs and therefore may require further investigation. 
We also tested the use of SCR7 and L755507 to increase HDR in PGCs but we did not observe any improvement 
or toxicity. SCR7 and L755507 are small molecules reported to increase CRISPR-mediated HDR by inhibiting 
NHEJ in some cell types34,53. Concentration of these inhibitors may need to be optimised for PGCs. Use of these 
inhibitors and other reported HDR enhancers such as RS-176 merit further investigation in PGCs.
Why we do observe such high HDR rates in avian PGCs using SpCas9-HF1? It is possible that many PGCs 
targeted with SpCas9-WT do not survive due to the induction of another round of cleavage of the HDR-edited 
site. Germ cells from many vertebrate species have been shown to undergo programmed cell death when exposed 
to reagents causing DSBs as a mechanism to protect the integrity of the germline genome77–81. In our experiments, 
we used plasmid delivery of SpCas9-WT which has been shown to have some toxicity in human embryonic stem 
cells compared to ribonucleoprotein (RNP) delivery82. In human pluripotent stem cells, it has been reported that 
the induction of a single DSB by SpCas9-WT is toxic even in the absence of the induction of multiple DSBs or 
off-target mutagenesis83. This toxicity is P53-dependent and the induction of P53 by Cas9 leads to apoptosis or 
cell cycle arrest in the G1 phase where NHEJ is predominant thereby reducing the efficiency CRISPR/Cas9 preci-
sion genome editing83,84. Depending on the gRNA and loci, the sustained expression of SpCas9-WT from a plas-
mid increases the potential for re-cleaving of HDR-edited chromosomal targets as well as off-target mutagenesis. 
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Since the SpCas9-WT nuclease spends up to 6 hrs tightly bound to the cut ends of the DNA duplex66, the long 
residence time coupled with the high cleavage activity of SpCas9-WT probably increases the severity of genotoxic 
insult by preventing DNA repair, which may result in a stalled replication fork leading to cell cycle arrest or apop-
tosis and a decrease in overall HDR events. Indeed, inhibition of P53, a pro-apoptotic protein that is activated by 
DNA damage85, has been shown to increase the rate of HDR in human cells by preventing DNA damage response 
that results in apoptosis and allowing the cell cycle to progress83,84.
Conclusion
Our results demonstrate possible rapid introgression of specific haplotypes into primordial germ cells. These 
genomic tools will allow the validation of SNP and other chromosomal changes in poultry.
Materials and Methods
CRISPR Plasmids. PX459 V2.0 vector33 was used for expression of SpCas9-WT and sgRNA. The 
equivalent expression cassette (HF-PX459 V2.0) for SpCas9-HF1 and sgRNA was generated by transfer-
ring the domain containing the point mutations of SpCas9-HF1 into the coding sequence of SpCas9-WT 
in PX459 V2.0. A 1.4 kb region of the coding sequence of SpCas9-WT in PX459 V2.0 was excised using 
ApaI and PmlI restriction digest and replaced with a homologous 1.4 kb overlapping PCR fragment (Left 
primer, 5′-TTCCGCATCCCCTACTACGTGGGCCCCCTGGCCCGAGGGAACTCTC-3′ and right primer 
5′-TCCGGGAGTCCAGGATCTGTGCCACATGCTTTGTGATGGCGCGGGTTTC-3′) from the coding 
sequence of SpCas9-HF1 in VP12 vector45 using NEBuilder® HiFi DNA Assembly (New England Biolabs). PX459 
V2.0 was a gift from Feng Zhang (Addgene plasmid # 62988) while VP12 was a gift from Keith Joung (Addgene 
plasmid # 72247).
gRNA design and CRISPR/Cas9 vector construction. gRNA sequences were selected using 
CHOPCHOP gRNA design web tool (http://chopchop.cbu.uib.no/)86,87 and MIT gRNA design web tool (http://
crispr.mit.edu/) except where described otherwise. gRNA oligonucleotides were synthesized by Invitrogen and 
inserted into PX459 V2.0 and HF-PX459 V2.0 vectors using methods previously described in33. gRNA sequences 
are listed in Supplementary Table S1.
ssODN donors. ssODN donors were Ultramer® DNA Oligonucleotides synthesized by Integrated DNA 
Technologies (IDT). Donors were used at a concentration of 10 µM for transfections. See Supplementary Table S2 
for sequences of ssODN donors.
Animal usage. Fertile eggs were obtained from a flock of commercial Hyline layer hens maintained at the 
Roslin Institute. The GFP+/+ germ cells used in the experiments shown in Figs 3 and 4 were obtained by crossing 
the Roslin Green (ubiquitous GFP) line of transgenic chicken88 to produce homozygous fertile eggs for PGC 
derivations. Commercial and transgenic chicken lines were maintained and bred under UK Home Office License. 
All experiments were performed in accordance with relevant UK Home Office guidelines and regulations. The 
experimental protocol and studies were reviewed by the Roslin Institute Animal Welfare and Ethical Review 
Board (AWERB) Committee.
PGC culture. PGC lines were derived and cultured in FAOT medium as described in Whyte et al.11. Briefly, 
fertile eggs from Hyline layer lines or the Roslin Green line of transgenic chickens88 were incubated for 2.5 days 
and then 1 μl of embryonic blood was taken from the vasculature of stage 16 HH chick embryos89 and placed into 
FAOT medium. FAOT medium contains 1 × B-27 supplement (Thermo Fisher Scientific), 2.0 mM GlutaMax 
(Thermo Fisher Scientific), 1 × non-essential amino acids (Thermo Fisher Scientific), 1 × EmbryoMax nucle-
osides (Merck Millipore), 0.1 mM β-mercaptoethanol (Thermo Fisher Scientific), 0.2% ovalbumin (Sigma), 
1.2 mM pyruvate (Thermo Fisher Scientific), 0.15 mM CaCl2, 0.01% sodium heparin (Sigma), 4 ng/ml FGF2 
(R&D Systems), 25 ng/ml activin A (Peprotech) and 5 µg/ml ovotransferrin (Sigma) in Avian Knockout DMEM 
(osmolality: 250 mOsmol/kg, 12.0 mM glucose, calcium chloride free; Thermo Fisher Scientific, a custom mod-
ification of Knockout DMEM). PGC lines were expanded to 2.4 × 105 cells in 5 weeks before use in targeting 
experiments. GFP-PGCs were derived from transgenic chickens created by lentiviral methods88 and maintained 
at the National Avian Research Facility, Midlothian, UK.
PGC transfection. 200,000 PGCs were transfected with 1.5 µg of CRISPR vector and 0.4 µg of ssODN donor 
using Lipofectamine 2000 transfection reagent (Thermo Fisher Scientific). Cells were washed in Optimem I 
(Thermo Fisher Scientific) and incubated in suspension in Optimem I mixed with DNA and transfection reagent 
for 6 h. PGCs were then centrifuged and resuspended in FAOT medium. PGCs were treated with 0.6 µg/ml puro-
mycin 24 h post-transfection for 48 h to enrich for transfected cells and then expanded in culture for two weeks to 
eliminate transient CRISPR expression and then used to isolate genomic DNA to measure targeting efficiencies 
or isolate single cells. To test NHEJ inhibitors, PGCs were treated with SCR7 (Sigma-Aldrich) at a concentration 
of 1 mM or L755507 (Sigma-Aldrich) at a concentration of 5 µM for 24 h after transfection followed by puromycin 
treatment for 48 h.
Isolation of single-cell clonal populations. PGCs were seeded manually or sorted using a FACSAria III 
(BD Biosciences) into 96-well plates at 1 cell per well in 110 µL FAOT medium and cultured for 2 weeks. Once 
cell density reached 30–50%, PGCs were transferred into a 48-well plate and subsequently into a 24-well plate for 
further expansion to isolate genomic DNA for analysis of mutation genotype.
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Genomic DNA isolation and PCR amplification of target region. Genomic DNA was extracted from 
PGCs using QIAMP Micro Kit (Qiagen) according to the manufacturer’s instruction. Specific primers for PCR 
amplification of sgRNA target sites were designed using primer3 software (http://primer3.ut.ee/)90,91. Primers 
were designed to anneal outside the homology arms of HDR templates. List of primer sequences are listed in 
Supplementary Table S3. All PCR amplifications were performed using 100 ng of genomic DNA and Q5® Hot 
Start High-Fidelity DNA polymerase (NEB) or Phusion® High-Fidelity DNA polymerase (NEB) according to 
the manufacturer’s protocol. Primer annealing temperatures were calculated using the online NEB Tm calculator 
(https://tmcalculator.neb.com).
Analysis of gRNA targeting efficiency by T7 endonuclease I mismatch assay. T7 endonucle-
ase I assay was performed by treating 200 ng of PCR DNA with 10 units of T7 endonuclease I in NEBuffer™ 2 
buffer and incubated according to the manufacturer’s instruction (NEB). The digestion products were resolved 
on 1% agarose gel containing Gelred® nucleic acid gel stain (Biotium) and ImageJ (https://imagej.net) was used 
to quantitate band intensities. The targeting efficiency was calculated using the equation 100 × (1 − (1 − fraction 
cleaved)1/2)92.
HDR quantification by EcoRI restriction digestion. Restriction site sequences were incorporated into 
the target site to quantify HDR. All restriction enzyme digestion reactions were performed by treating 200 ng 
of PCR DNA with 10 units of restriction enzyme (EcoRI-HF (NEB #R3101S), BamHI-HF (NEB #R3136S), AfeI 
(NEB #R0652S), AatII (NEB #R0117S)) in CutSmart buffer (NEB) incubated at 37 °C for 1 h. The digestion prod-
ucts were resolved on 1% agarose gel containing Gelred® nucleic acid gel stain (Biotium). ImageJ software was 
used to quantitate band intensities. The percentage of HDR was calculated as described in51 using the equation 
(b + c/a + b + c) × 100, where ‘a’ is the band intensity of uncleaved DNA substrate and ‘b’ and ‘c’ are the cleavage 
products.
HDR and INDEL quantification by flow cytometry. Live cells were gated and then GFP and BFP fluo-
rescence was detected using a Fortessa X20 (BD Biosciences). Cytometry data was analysed using FlowJo® V7.0 
(FlowJo, LLC).
DNA sequencing and bioinformatic analysis. PCR products were directly sequenced to analyse muta-
tion genotypes of single cell clones using PCR primers or PCR products were cloned into pGEM-T Easy vector 
(Promega #A137A) and sequenced using T7 promoter forward primer by Sanger sequencing. Sequencing data 
was analysed and viewed using SeqMan Pro 13 (Lasergene 13, DNASTAR) and FinchTV 1.4.0 (Geospiza, Inc.). 
PCR Sanger sequencing traces were analysed with the TIDE analysis web tool (https://tide.deskgen.com/) to 
detect INDELs in a population.
Data Availability
Plasmid HF-PX459 V2.0 will be available from Addgene. Data sharing is not applicable to this article as no data-
sets were generated or analysed during the current study.
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